Drug intelligence / Profile preview

IMD-1005

Development stage: Unknown
Lead developer: Affinity Biopharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IMD-1005 is a monoclonal antibody developed by Affinity Biopharmaceutical that targets CD47, a transmembrane protein overexpressed on various cancer cells. CD47 functions as a "don't eat me" signal by interacting with signal regulatory protein alpha (SIRPα) on macrophages, thereby inhibiting phagocytosis. By binding to CD47, IMD-1005 blocks this inhibitory signal, enabling the innate immune system to recognize and eliminate tumor cells. It is currently in Phase 1 development for the treatment of advanced solid tumors.

Targets

CD47 (Cluster of Differentiation 47)

Beyond the preview

Go deeper on IMD-1005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMD-1005.

Explore the full profile